![\"\"](\"https:\/\/www.lunit.io\/wp-content\/uploads\/2026\/04\/Lunit-x-Lexington-Clinic-300x169.png\")
<\/p>\nLunit highlights enterprise AI adoption and FDA-cleared advancements at SBI 2026<\/i><\/b><\/i><\/b><\/p>\n
<\/p>\n
SEOUL, South Korea, April 17, 2026<\/b>\u00a0\u2014 At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced accelerating clinical adoption across the U.S., a full-scale enterprise deployment of its AI-powered breast cancer ecosystem, and FDA clearance of its next-generation 3D mammography AI.<\/p>\n
Lexington Clinic Adopts Full Breast Cancer Ecosystem<\/b><\/b><\/p>\n
Lexington Clinic, Central Kentucky\u2019s largest and oldest physician-owned multi-specialty medical group (serving more than 350 providers), has implemented Lunit\u2019s complete AI-powered breast cancer ecosystem.<\/p>\n
The deployment spans:<\/p>\n
\u00b7\u00a0Detection<\/b>\u00a0with Lunit INSIGHT\u00ae Breast Suite for mammography (MMG) and digital breast tomosynthesis (DBT)<\/p>\n
\u00b7\u00a0Quality optimization<\/b>\u00a0with Analytics\u2122 and Volpara\u00ae Live\u2122<\/p>\n
\u00b7\u00a0Volumetric breast density assessment\u00a0<\/b>with Volpara\u00ae Scorecard\u2122<\/p>\n
\u00b7\u00a0Risk assessment<\/b>\u00a0with Risk Pathways\u2122, integrated into clinical workflows<\/p>\n
\u00b7\u00a0Mammography tracking<\/b>\u00a0with Patient Hub\u2122<\/p>\n
The implementation signals a shift toward end-to-end AI integration across the breast care continuum\u2014from risk to detection to quality\u2014within a single software suite.<\/p>\n
\u201cOur goal is to deliver the highest standard of care while keeping workflows efficient and consistent,\u201d said Angie Hall, Breast Center Manager at Lexington Clinic. \u201cBringing risk, detection, and quality into one ecosystem improves coordination across our team and supports more confident, earlier decision-making for every patient.\u201d<\/p>\n
Adoption Across the Americas Surpasses 330 Sites<\/b><\/b><\/p>\n
Over the past year, Lunit has expanded to more than 330 screening sites across the Americas, supporting approximately one million screening mammograms annually.<\/p>\n
The milestone highlights a broader industry shift: while AI validation is well established, real-world adoption at scale is now the key differentiator.<\/p>\n
\u201cAcross the Americas, we\u2019re seeing a clear move from evaluation to enterprise-wide implementation,\u201d said Craig Hadfield, CEO of Lunit International. \u201cProviders are moving beyond pilots into daily clinical use. Reaching more than 330 sites and supporting one million screenings annually reflects sustained, real-world adoption\u2014where AI is delivering value in routine practice.\u201d<\/p>\n
Real-World Clinical Impact: Radiology Consultants of Iowa<\/b><\/b><\/p>\n
At Radiology Consultants of Iowa (RCI), one of the largest radiology groups in the state, Lunit INSIGHT DBT is already embedded in routine clinical workflows, demonstrating the impact of AI beyond the study setting.<\/p>\n
\u201cAfter six months of using AI in our daily workflow, it\u2019s become part of how we read,\u201d said Robert J. Dolan, DO, breast imaging specialist at RCI. \u201cIt gives us added confidence\u2014especially in subtle cases\u2014and helps ensure we don\u2019t miss what matters most.\u201d<\/p>\n
At SBI, Dr. Dolan will review cases each day in Lunit\u2019s booth, highlighting where AI positively impacts his interpretation, giving attendees a chance to discuss real-world adoption.<\/p>\n
FDA Clearance of Next-Generation 3D AI with Current-Prior Comparison<\/b><\/b><\/p>\n
As providers move into routine AI use, flexibility in how algorithms are deployed is becoming increasingly important. Lunit announced that Version 1.2 of its 3D mammography algorithm has received clearance from the U.S. Food and Drug Administration (FDA).<\/p>\n
The updated version introduces current-prior comparisons and multiple operating thresholds, enabling providers to tailor AI performance to their clinical environment.<\/p>\n
Key enhancements include:<\/p>\n
\u00b7 Current-prior comparison (CPC) provides AI findings for the current exam and up to two prior exams<\/p>\n
\u00b7 Three selectable thresholds, supporting different sensitivity and specificity trade-offs<\/p>\n
\u00b7 Access to Volpara\u00ae Scorecard\u2122 volumetric breast density measures along with AI scores<\/p>\n
These updates reinforce Lunit\u2019s focus on practical usability\u2014giving clinicians greater control over how AI is applied in daily practice.<\/p>\n","protected":false},"author":9,"featured_media":4700,"parent":0,"template":"","media-hub-type":[36],"class_list":["post-4701","media-hub","type-media-hub","status-publish","has-post-thumbnail","hentry","media-hub-type-cancer-screening"],"acf":[],"yoast_head":"\n